Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma.

Abstract excerpt

Patients with lung adenocarcinoma who have never smoked (NSLA) and lack key driver mutations, such as those in the EGFR and ALK genes, face limited options for targeted therapies. They also tend to have poorer outcomes with immune checkpoint inhibitors than lung cancer patients who have a history of smoking. The proteogenomic profile of nonsmoking lung adenocarcinoma patients without these oncogenic driver...

Topics

Join the communities discussing this publication.

• Adenocarcinoma of Lung
• Anaplastic Lymphoma Kinase
• ErbB Receptors
• Lung Neoplasms
• Prognosis